Chromobox Homolog 4 Is Correlated with Prognosis and Tumor Cell Growth in Hepatocellular Carcinoma

详细信息    查看全文

• 作者：Boqing Wang MD (1) (2)
  Jianjun Tang MD ; PhD (2)
  Dan Liao MD (2)
  Gang Wang MD (2)
  Meifang Zhang MD (2)
  Yi Sang PhD (2)
  Jingying Cao MD (2)
  Yuanzhong Wu PhD (2)
  Ruhua Zhang MD (2)
  Shengping Li MD (2)
  Wei Ding MD (1)
  Guoqing Zhang MD (1)
  Tiebang Kang PhD (2)
  
• 刊名：Annals of Surgical Oncology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：20
• 期：3-supp
• 页码：684-692
• 全文大小：685 KB
• 参考文献：1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. / Gastroenterology. 2012;142:1264-3.e1.
  2. Chen D, Xing W, Hong J, et al. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. / Ann Surg Oncol. 2012;19:3556-5. CrossRef
  3. Li JJ, Pan K, Gu MF, et al. Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. / Chin J Cancer. 2013;32:141-. CrossRef
  4. Yi Y, Wu H, Gao Q, et al. Interferon regulatory factor (IRF)-1 and IRF-2 are associated with prognosis and tumor invasion in HCC. / Ann Surg Oncol. 2013;20:267-6. CrossRef
  5. Song TJ, Fong Y, Cho SJ, et al. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. / J Surg Oncol. 2012;106:84-. CrossRef
  6. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. / Cell Death Dis. 2011;2:e204. CrossRef
  7. Vandamme J, Volkel P, Rosnoblet C, Le Faou P, Angrand PO. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. / Mol Cell Proteomics. 2011;10:M110 002642.
  8. Gao Z, Zhang J, Bonasio R, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. / Mol Cell. 2012;45:344-6. CrossRef
  9. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. / Nat Rev Cancer. 2009;9:773-4. CrossRef
  10. Forzati F, Federico A, Pallante P, et al. CBX7 is a tumor suppressor in mice and humans. / J Clin Invest. 2012;122:612-3. CrossRef
  11. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. / Cancer Cell. 2011;20:563-5. CrossRef
  12. Yang L, Lin C, Liu W, et al. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. / Cell. 2011;147:773-8. CrossRef
  13. Xu S, Feng Z, Zhang M, et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. / Oncogene. 2011;30:2219-9. CrossRef
  14. Hong J, Hu K, Yuan Y, et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. / J Clin Invest. 2012;122:2165-5. CrossRef
  15. Tang QL, Xie XB, Wang J, et al. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. / J Natl Cancer Inst. 2012;104:749-3. CrossRef
  16. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). / Pathol Res Pract. 1993;189:862-. CrossRef
  17. Xu S, Wu Y, Chen Q, et al. hSSB1 regulates both the stability and the transcriptional activity of p53. / Cell Res. 2013;23:423-5. CrossRef
  18. Kang T, Wei Y, Honaker Y, et al. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. / Cancer Cell. 2008;13:36-7. CrossRef
  19. Chen R, Zhu D, Ye X, Shen D, Lu R. Establishment of three human liver carcinoma cell lines and some of their biological characteristics in vitro. / Sci Sin. 1980;23:236-7.
  20. Wang JB. Establishment and some characteristics of a hepatoma cell line (QGY-7703). / Zhonghua Zhong Liu Za Zhi. 1981;3:241-.
  21. Kagey MH, Melhuish TA, Wotton D. The polycomb protein Pc2 is a SUMO E3. / Cell. 2003;113:127-7. CrossRef
  22. Ismail IH, Gagne JP, Caron MC, et al. CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. / Nucleic Acids Res. 2012;40:5497-10. CrossRef
  23. O’Loghlen A, Munoz-Cabello AM, Gaspar-Maia A, et al. MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. / Cell Stem Cell. 2012;10:33-6. CrossRef
  24. Pallante P, Federico A, Berlingieri MT, et al. Loss of the / CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. / Cancer Res. 2008;68:6770-. CrossRef
  25. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. / Annu Rev Pathol. 2009;4:399-15. CrossRef
  26. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. / Nat Rev Cancer. 2009;9:153-6. CrossRef
  27. Wang X, Meng X, Sun X, et al. Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. / Cell Cycle. 2009;8:1567-0. CrossRef
  28. Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. / J Gastrointestin Liver Dis. 2008;17:411-.
  29. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. / Nat Rev Cancer. 2006;6:846-6. CrossRef
  30. Ruddock-D’Cruz NT, Prashadkumar S, Wilson KJ, et al. Dynamic changes in localization of Chromobox (Cbx) family members during the maternal to embryonic transition. / Mol Reprod Dev. 2008;75:477-8.
  31. Huynh H. Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. / Carcinogenesis. 2004;25:1485-4. CrossRef
  32. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR, Bradford AP. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. / Hum Pathol. 2008;39:21-. CrossRef
  33. Roscic A, Moller A, Calzado MA, et al. Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. / Mol Cell. 2006;24:77-9. CrossRef
  34. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. / Cell. 2009;136:629-1. CrossRef
  
• 作者单位：Boqing Wang MD (1) (2)
  Jianjun Tang MD, PhD (2)
  Dan Liao MD (2)
  Gang Wang MD (2)
  Meifang Zhang MD (2)
  Yi Sang PhD (2)
  Jingying Cao MD (2)
  Yuanzhong Wu PhD (2)
  Ruhua Zhang MD (2)
  Shengping Li MD (2)
  Wei Ding MD (1)
  Guoqing Zhang MD (1)
  Tiebang Kang PhD (2)
  
  1. Department of Hepatopancreatobiliary Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang, China
  2. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
  
• ISSN：1534-4681

文摘

Background Chromobox homolog 4 (CBX4) is a member of the chromobox family of Polycomb group proteins involved in the chromatin remodeling and transcriptional regulation. However, its clinical relevance in hepatocellular carcinoma (HCC) has not yet been explored. Methods Immunohistochemistry was used to analyze cytoplasmic expression of CBX4 in 246 HCC specimens. The expression of CBX4 in HCC cell lines and LO2 was detected by Western blot test. Cell cycle and MTT assays were used to determine the changes of cell growth capacity. The expression of downstream genes related to proliferation was?detected by Western blot test. Results The expression of CBX4 was up-regulated in multiple HCC cell lines and clinical samples. Although the CBX4 protein was detectable in both nucleus and cytoplasm in HCC tumor tissues, the high expression of CBX4 in cytoplasm was correlated with the α-fetoprotein level in serum (P?=?0.036), tumor size (P?=?0.029), pathologic differentiation (P?=?0.033), and tumor, node, metastasis classification system stages (P?=?0.032). Moreover, HCC patients who had a high level of CBX4 in cytoplasm had a shorter overall survival (P?=?0.003) and recurrence-free survival (P?=?0.012). Indeed, using HCC cell line, knockdown of CBX4 led to down-regulating proliferating cell nuclear antigen and cyclin E2 as well as up-regulating p16, followed by decreased cell proliferation and impaired cell cycle progression. Conclusions The cytoplasmic CBX4 protein may be a useful prognostic biomarker and a potential therapeutic target for HCC.